SEEBRI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Seebri, and when can generic versions of Seebri launch?
Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has ninety-nine patent family members in thirty-two countries.
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri
A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SEEBRI?
- What are the global sales for SEEBRI?
- What is Average Wholesale Price for SEEBRI?
Summary for SEEBRI
International Patents: | 99 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 3 |
Patent Applications: | 3,885 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SEEBRI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SEEBRI |
DailyMed Link: | SEEBRI at DailyMed |
Recent Clinical Trials for SEEBRI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Saskatchewan | Phase 4 |
Sunovion Respiratory Development Inc. | Phase 1 |
US Patents and Regulatory Information for SEEBRI
SEEBRI is protected by two US patents.
Patents protecting SEEBRI
Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhaler device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SEEBRI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SEEBRI
See the table below for patents covering SEEBRI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Ecuador | SP066987 | DISPOSITIVO INHALADOR | ⤷ Sign Up |
European Patent Office | 1274406 | FORMULATIONS PHARMACEUTIQUES POUR INHALATEURS DE POUDRE SECHE SOUS FORME DE PASTILLES DURES (PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD-PELLETS) | ⤷ Sign Up |
Cyprus | 1112338 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2004089374 | ⤷ Sign Up | |
China | 100569238 | ⤷ Sign Up | |
Denmark | 1274406 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEEBRI
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1267866 | 493 | Finland | ⤷ Sign Up | |
1267866 | 479 | Finland | ⤷ Sign Up | |
2435025 | 19C1040 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220 |
1267866 | C300651 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN; REGISTRATION NO/DATE: EU/1/13/862/001-006 20130919 |
1267866 | CR 2013 00015 | Denmark | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003 |
1267866 | 92393 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |